1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Radiopharm Theranostics Limited

Radiopharm Theranostics Limited

RADX
Radiopharm Theranostics LimitedUS flagNASDAQ Capital Market
1.01
USD
-0.02
- -
1.30MMarket Cap

Total Valuation

Radiopharm Theranostics Limited carries a market capitalization of 1.30M, placing it among publicly traded companies globally.

Market Cap1.30M
Enterprise ValueN/A

Share Statistics

Radiopharm Theranostics Limited currently has 2.20B shares outstanding.

Shares Outstanding2.20B
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

PE RatioN/A
PS RatioN/A
PB Ratio300.07
P/TBV Ratio3,069.87
P/FCF RatioN/A
P/OCF RatioN/A

Financial Position

Radiopharm Theranostics Limited maintains a current ratio of 3.37, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

Current Ratio3.37
Quick Ratio3.25
Debt / EquityN/A
Debt / EBITDAN/A
Interest CoverageN/A

Stock Price Statistics

Radiopharm Theranostics Limited's stock has declined approximately -82.2807% over the past 52 weeks. The 50-day moving average sits at 1.88, while the 200-day moving average is 3.86.

Beta (5Y)N/A
52-Week Price Change-82.2807%
50-Day Moving Average1.88
200-Day Moving Average3.86
Average Volume (20 Days)N/A

Balance Sheet

Total book value stands at 53.20M, with working capital of 31.21M providing operational flexibility.

Cash & Cash Equivalents36.44M
Total DebtN/A
Net Debt-36.44M
Equity (Book Value)53.20M
Book Value Per Share0.02
Working Capital31.21M

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-0.40
FCF YieldN/A

Scores

Radiopharm Theranostics Limited posts an Altman Z-Score of 233.63, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score233.63